AstraZeneca stock at GBX 12,552.00 on September 25, 2026
Published on 09/28/2026 at 21:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock closed at GBX 12,552.00 on the London Stock Exchange on September 25, 2026, up 1.23 percent from the previous close. The company’s latest reported development is separate from that trading session.
U.S. regulatory review
On September 25, 2026, AstraZeneca said the U.S. Food and Drug Administration had accepted and granted Priority Review to its supplemental Biologics License Application for Imfinzi, or durvalumab, in combination with enfortumab vedotin. The application covers patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy, according to the company’s release.
AstraZeneca said the application is based on results from the VOLGA Phase III trial. In a planned interim analysis, perioperative treatment with Imfinzi and neoadjuvant enfortumab vedotin showed statistically significant and clinically meaningful improvements in event-free survival and overall survival compared with radical cystectomy, with or without approved adjuvant treatment. The company said the FDA’s action date is anticipated during the fourth quarter of 2026, subject to the agency’s review process, in the same announcement.
Trial details
The VOLGA trial randomized 695 patients across 182 centers in 25 countries, AstraZeneca said. The Phase III study evaluated perioperative Imfinzi, with or without Imjudo, alongside neoadjuvant enfortumab vedotin for patients undergoing radical cystectomy who were not eligible for or had declined cisplatin-based chemotherapy.
